- Home
- REBN vs GLTO Comparison
REBN vs GLTO Comparison
Compare REBN & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REBN
- GLTO
- Stock Information
- Founded
- REBN 2015
- GLTO 2011
- Country
- REBN United States
- GLTO Denmark
- Employees
- REBN N/A
- GLTO N/A
- Industry
- REBN Restaurants
- GLTO Biotechnology: Pharmaceutical Preparations
- Sector
- REBN Consumer Discretionary
- GLTO Health Care
- Exchange
- REBN Nasdaq
- GLTO Nasdaq
- Market Cap
- REBN 12.8M
- GLTO 4.5M
- IPO Year
- REBN 2022
- GLTO 2020
- Fundamental
- Price
- REBN $3.00
- GLTO $3.91
- Analyst Decision
- REBN
- GLTO Buy
- Analyst Count
- REBN 0
- GLTO 1
- Target Price
- REBN N/A
- GLTO $10.00
- AVG Volume (30 Days)
- REBN 64.0K
- GLTO 19.4K
- Earning Date
- REBN 08-18-2025
- GLTO 08-11-2025
- Dividend Yield
- REBN N/A
- GLTO N/A
- EPS Growth
- REBN N/A
- GLTO N/A
- EPS
- REBN N/A
- GLTO N/A
- Revenue
- REBN $6,103,732.00
- GLTO N/A
- Revenue This Year
- REBN $335.98
- GLTO N/A
- Revenue Next Year
- REBN N/A
- GLTO N/A
- P/E Ratio
- REBN N/A
- GLTO N/A
- Revenue Growth
- REBN 3.38
- GLTO N/A
- 52 Week Low
- REBN $1.03
- GLTO $2.01
- 52 Week High
- REBN $8.30
- GLTO $16.07
- Technical
- Relative Strength Index (RSI)
- REBN 57.62
- GLTO 59.96
- Support Level
- REBN $2.61
- GLTO $3.32
- Resistance Level
- REBN $3.16
- GLTO $3.61
- Average True Range (ATR)
- REBN 0.20
- GLTO 0.22
- MACD
- REBN 0.06
- GLTO -0.01
- Stochastic Oscillator
- REBN 68.46
- GLTO 79.09
About REBN Reborn Coffee Inc.
Reborn Coffee Inc is an operator and franchisor of retail locations and kiosks that focus on serving specialty-roasted coffee. It is an company that strives for constant improvement in the coffee experience through exploration of new technology and premier service, guided by traditional brewing techniques. The company operates in one reportable segment, consisting of both the wholesale and retail sales of coffee, water, and other beverages.
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.